Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.520
+0.010 (0.66%)
At close: Jul 3, 2025, 1:00 PM
1.511
-0.009 (-0.61%)
After-hours: Jul 3, 2025, 1:23 PM EDT
Cocrystal Pharma Employees
Cocrystal Pharma had 11 employees as of December 31, 2024. The number of employees decreased by 1 or -8.33% compared to the previous year.
Employees
11
Change (1Y)
-1
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$1,440,818
Market Cap
15.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
COCP News
- 4 weeks ago - Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference - GlobeNewsWire
- 5 weeks ago - Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - GlobeNewsWire
- 5 weeks ago - Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 7 weeks ago - Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 2 months ago - Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - GlobeNewsWire
- 2 months ago - Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 - GlobeNewsWire